Классификационные критерии антифосфолипидного синдрома и его некритериальные проявления

УДК 616.72-002.77-07

Аннотация

Резюме. Вопросы по критериальным признакам антифосфолипидного синдрома (АФС), в частности о необходимости включения некоторых клинических проявлений, а также серологических маркёров, отличных от классических, остаются актуальными. В обзоре приведены предлагаемые профили некритериальных проявлений АФС, обсуждается необходи- мость пересмотра классификационных критериев АФС.

Литература:

1. Решетняк Т.М. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56–71. DOI: 10.14412/1995–4484–2014– 56–71. 

2. Насонов Е.Л. Антифосфолипидный синдром. М.: Литтеpра, 2004. 434 с.

3. Schreiber K., Sciascia S., de Groot P.G. et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4:17103. DOI: 10.1038/ nrdp.2017.103. 

4. Agmon-Levin N., Shoenfeld Y. The spectrum between antiphos- pholipid syndrome and systemic lupus erythematosus. Clin Rheu- matol. 2014;33(3):293–5. DOI: 10.1007/s10067–014–2486–5. 

5. Volkov I., Seguro L., Leon E.P. et al. Profiles of criteria and non-cri- teria antiphospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome. Auto Immun High- lights. 2020;11(1):8. DOI: 10.1186/s13317–020–00131–3. 

6. Roggenbuck D., Egerer K., von Landenberg P. et al. Antiphospho- lipid antibody profiling: time for a new technical approach? Auto- immun Rev. 2012;11(11):821–6. DOI: 10.1016/j.autrev.2012.02.016. 

7. Zuily S., Clerc-Urmès I., Bauman C., et al; APS ACTION Investi- gators. Cluster analysis for the identification of clinical pheno- types among antiphospholipid antibody-positive patients from the APS ACTION Registry. Lupus. 2020:961203320940776. DOI: 10.1177/0961203320940776. 

8. Yelnik C.M., Urbanski G., Drumez E. et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus. 2017;26(2):163–9. DOI: 10.1177/0961203316657433. 

9. Pengo V., Ruffatti A., Legnani C. et al. Incidence of a first throm- boembolic event in asymptomatic carriers of high-risk antiphos- pholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714–8. DOI: 10.1182/blood-2011–03–340232. 

10. Mekinian A., Alijotas-Reig J., Carrat F. et al; on the behalf of the SNFMI and the European Forum on Antiphospholipid Antibo- Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospec- tive study. Autoimmun Rev. 2017;16(7):730–4. DOI: 10.1016/j.aut- rev.2017.05.006. 

11. Abreu M.M., Danowski A., Wahl D.G. et al. The relevance of “non- criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Tech- nical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(5):401–14. DOI: 10.1016/j.aut- rev.2015.01.002. 

12. Mekinian A., Bourrienne M.C., Carbillon L. et al. Non-conven- tional antiphospholipid antibodies in patients with clinical obstetrical APS: Prevalence and treatment efficacy in pregnan- Semin Arthritis Rheum. 2016;46(2):232–7. DOI: 10.1016/j.sem- arthrit.2016.05.006. 

13. Sciascia S., Bertolaccini M.L. Antibodies to phosphatidylserine/ prothrombin complex and the antiphospholipid syndrome. Lupus. 2014;23(12):1309–12. DOI: 10.1177/0961203314538332. 

14. Shi H., Zheng H., Yin Y.F. et al. Antiphosphatidylserine/prothrom- bin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med. 2018;56(4):614– 24. DOI: 10.1515/cclm-2017–0502.
15. Sciascia S., Sanna G., Murru V. et al. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A sys- tematic review. Thromb Haemost. 2014;111(2):354–64. DOI: 10.1160/ TH13–06–0509.
16. Liu T., Gu J., Wan L. et al. “Non-criteria” antiphospholipid antibo- dies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort. Arthritis Res Ther. 2020;22(1):33. DOI: 10.1186/ s13075–020–2131–4.
17. Roggenbuck D., Borghi M.O., Somma V., et al. Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. Arthritis Res Ther. 2016;18(1):111. DOI: 10.1186/s13075–016–1018-x.
18. Nalli C., Somma V., Andreoli L. et al. Anti-phospholipid IgG anti- bodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases. Auto Immun Highlights. 2018;9(1):6. DOI: 10.1007/s13317–018–0106–0.
19. Funke A., Staub H.L., Monticielo O.A. et al Non-criteria antiphos- pholipid antibodies: a narrative review. Rev Assoc Med Bras (1992). 2020;66(11):1595–601. DOI: 10.1590/1806–9282.66.11.1595.
20. Barbhaiya M., De Abreu M.M., Amigo M.C. Needs-assessment sur- vey for the update of the current antiphospholipid syndrome (APS) classification criteria. Ann Rheum Dis. 2015;74(Suppl 2):1087.3– 1087. DOI: 10.1136/annrheumdis-2015-eular.1330.
21. Barbhaiya M., Ercan D., Ahmadzadex Y., et al. OP0097 Develop- ment of new international classification criteria for antiphospho- lipid syndrome: Phase III case collection results. Ann Rheum Dis. 2020;79(Suppl 1):64.2–64. DOI: 10.1136/annrheumdis-2020-eu- lar.5294/
22. da Rosa P.G., Bettencourt P., Rodríguez-Pintó I., Cervera R., Espi- nosa G. “Non-criteria” antiphospholipid syndrome: A nomencla- ture proposal. Autoimmun Rev. 2020;19(12):102689. DOI: 10.1016/j. 2020.102689.

23. Hughes G.R., KhamashtaM.A.Seronegative antiphospho- lipid syndrome. Ann Rheum Dis. 2003;62(12):1127. DOI: 10.1136/ ard.2003.006163.


24. Rodriguez-Garcia J.L., Bertolaccini M.L., Cuadrado M.J. et al. Clini- cal manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ‘seronegative APS’). Ann Rheum Dis. 2012;71(2):242–4. DOI: 10.1136/annrheum- dis-2011–200614.
25. Pignatelli P., Ettorre E., Menichelli D. et al. Seronegative antiphos- pholipid syndrome: refining the value of “non-criteria” anti- bodies for diagnosis and clinical management. Haematologica. 2020;105(3):562–72. DOI: 10.3324/haematol.2019.221945.
26. Kalashnikova L., Stoynovich L., Kovalyv V. et al. Sneddon`s syn- drome and the primary antiphospholipid syndrome. Cerebrovas- cular Dis. 1994;4:76–82.
27. Asherson R.A., Piette J.C., Cervera R. “Primary”, “secondary”, “seronegative”, “catastrophic” and other subset of the antipho- spolipid syndrome. In: The Antiphospholipid Syndrome II: Autoimmune thrombosis. Eds. R.A. Asherson, J.C. Piette, R. Cer- vera, Y. Shoenfeld. Elsivier: Science, 2002. 285–96. DOI: 10.1016/ B978–044450987–1/50029–2.
28. Samanta D., Cobb S., Arya K. Sneddon syndrome: A comprehen- 
sive overview. J Stroke Cerebrovasc Dis. 2019;28(8):2098–108. DOI: 
1016/j.jstrokecerebrovasdis.2019.05.013. 

29. Conti F., Capozzi A., Truglia S. et al. The mosaic of “seronegative” 
antiphospholipid syndrome. J Immunol Res. 2014;2014:389601. 
DOI: 10.1155/2014/389601. 

30. Насонов Е.Л., Решетняк Т.М., Патрушев Л.И. и др. Мутации 
Leiden, G20210А в гене протромбина и антифосфолипидные антитела при системной красной волчанке и антифосфо- липидном синдроме. Терапевтический архив. 2000;(5):34–8. 
31. Berman H., Ugarte-Gil M.F., Espinosa G. et al. Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome? Clin Exp Rheumatol. 2013;31(6): 926–32. 

32. Diz-Kucukkaya R., HancerV.S., Artim-Esen B. et al. The preva- lence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome. J Thromb Thrombolysis. 2010;29(3):303–9. DOI: 10.1007/s11239–009–0356–9. 

33. Cervera R., Conti F., Doria A. et al. Does seronegative antiphos- pholipid syndrome really exist? Autoimmun Rev. 2012;11(8):581– 4. DOI: 10.1016/j.autrev.2011.10.017. 

34. Pons-Estel G.J., Andreoli L., Scanzi F. et al. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Auto- immun. 2017;76:10–20. DOI: 10.1016/j.jaut.2016.10.004. 

35. Marx-Deseure A., Labreuche J., Launay D. et al. Are pregnancies with lupus but without APS of good prognosis? Autoimmun Rev. 2020;19(4):102489. DOI: 10.1016/j.autrev.2020.102489. 

36. Pericleous C., Ferreira I., Borghi O. et al. Measuring IgA anti- β2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome. PLoS One. 2016;11(6): e0156407. DOI: 10.1371/jour- nal.pone.0156407. 

37. Miyakis S., Lockshin M.D., Atsumi T. et al. International con- sensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306. DOI: 10.1111/j.1538–7836.2006.01753.x. 

38. Asherson R.A. New subsets of the antiphospholipid syndrome in 2006: “PRE-APS” (probable APS) and microangiopathic antiphos- pholipid syndromes (“MAPS”). Autoimmun Rev. 2006;6(2):76–80. DOI: 10.1016/j.autrev.2006.06.008. 

39. Alijotas-Reig J., Esteve-Valverde E., Ferrer-Oliveras R. et al; EUROAPS Study Group. Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies. Med Clin (Barc). 2018;151(6):215–22. [Article in English, Spanish]. DOI: 10.1016/j.medcli.2017.11.017. 

40. Alijotas-Reig J., Esteve-Valverde.E, Ferrer-Oliveras R. et al; EUROAPS Study Group. Comparative study of obstetric antiphos- pholipid syndrome (OAPS) and non-criteria obstetric APS (NC- OAPS): report of 1640 cases from the EUROAPS registry. Rheuma- tology (Oxford). 2020;59(6):1306–14. DOI: 10.1093/rheumatology/ kez419. 

41. Alijotas-Reig J., Ferrer-Oliveras R.; EUROAPS Study Group. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a preliminary first year report. Lupus. 2012;21(7):766– DOI: 10.1177/0961203312440058. 

42. Meroni P.L., Chighizola C.B., Gerosa M. et al. Obstetric antiphos- pholipid syndrome: lobsters only? Or should we also look for selected red herrings? J Rheumatol. 2015;42(2):158–60. DOI: 10.3899/jrheum.141407. 

43. Clark C.A., Spitzer K.A., Laskin C.A. Obstetric antiphospholipid syndrome: has the black swan swallowed a red herring? J Rheu- matol. 2015;42(2):155–7. DOI: 10.3899/jrheum.140760. 

44. Simchen M.J., Dulitzki M., Rofe G. et al. High positive antibody titers and adverse pregnancy outcome in women with antiphos- pholipid syndrome. Acta Obstet Gynecol Scand. 2011;90(12):1428– 33. DOI: 10.1111/j.1600–0412.2011.01236.x.
45. Ruffatti A., Favaro M., Calligaro A. et al. Management of preg- nant women with antiphospholipid antibodies. Expert Rev Clin Immunol. 2019;15(4):347–58. DOI: 10.1080/1744666X.2019.1565995.
46. Mekinian A., Loire-Berson P., Nicaise-Roland P. et al. Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels. J Reprod Immunol. 2012;94(2):222–6. DOI:10.1016/j.jri.2012.02.004.
47. Ahluwalia J., Sreedharanunni S., Kumar N. et al. Thrombotic pri- mary antiphospholipid syndrome: the profile of antibody positi- vity in patients from North India. Int J Rheum Dis. 2016;19(9):903– DOI: 10.1111/1756–185X.12479.
48. Khogeer H., Alfattani A., Al Kaff M. et al. Antiphosphatidylse- rine antibodies as diagnostic indicators of antiphospholipid syn- Lupus. 2015;24(2):186–90. DOI: 10.1177/0961203314552462.
49. Lo H.W., Chen C.J., Tsai E.M. Pregnancy outcomes for women with non-criteria antiphospholipid syndrome after anticoagu- lant therapy. Eur J Obstet Gynecol Reprod Biol. 2020;244:205–7. DOI: 10.1016/j.ejogrb.2019.11.002.
50. Ofer-Shiber S., Molad Y. Frequency of vascular and pregnancy mor- bidity in patients with low vs. moderate-to-high titers of antiphos- pholipid antibodies. Blood Coagul Fibrinolysis. 2015;26(3):261–6. DOI: 10.1097/MBC.0000000000000218.
51. Arachchillage D.R.J., Laffan M. Pathogenesis and management of antiphospholipid syndrome. Br J Haematol. 2017;178(2):181–95. DOI: 10.1111/bjh.14632.
52. Arachchillage D.R., Machin S.J., Mackie I.J., Cohen H. Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. Thromb Haemost. 2015;113(1):13–9. DOI: 10.1160/TH14–05–0416.
53. Abdel-Wahab N., Lopez-Olivo M.A., Pinto-Patarroyo G.P., Suarez- Almazor M.E. Systematic review of case reports of antiphospho- lipid syndrome following infection. Lupus. 2016;25(14):1520–31. DOI: 10.1177/0961203316640912.
54. Насонов Е.Л. Коронавирусная болезнь 2019 (COVID-19): раз- мышления ревматолога. Научно-практическая ревматоло- гия. 2020;58(2):123–32. DOI: 10.14412/1995–4484–2020–123–132. 
55. Насонов Е.Л., Бекетова Т.В., Решетняк Т.М. и др. Коронави- русная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тром- бовоспаления и аутоиммунитета. Научно-практическая рев- матология. 2020;58(4):353–67. DOI: 10.47360/1995–4484–2020– 353–367.
56. Vassalo J., Spector N., de Meis E.et al. Antiphospholipid anti- bodies in critically ill patients with cancer: a prospective cohort J Crit Care. 2014;29(4):533–8. DOI: 10.1016/j.jcrc.2014.02.005.
57. Dlott J.S., Roubey R.A. Drug-induced lupus anticoagulants and antiphospholipid antibodies. Curr Rheumatol Rep. 2012;14(1):71– 8. DOI: 10.1007/s11926–011–0227–1.
58. Ruiz-Irastorza G., Hunt B.J., Khamashta M.A. A systematic review of secondary thromboprophylaxis in patients with antiphospho- lipid antibodies. Arthritis Rheum. 200715;57(8):1487–95. DOI: 10.1002/art.23109.
59. Sciascia S., Radin M., Bazzan M., Roccatello D. Novel diagnos- tic and therapeutic frontiers in thrombotic anti-phospholipid syndrome. Intern Emerg Med. 2017;12(1):1–7. DOI: 10.1007/s11739– 016–1596–2.
60. Решетняк Т.М., Войцеховская Б., Алекберова З.С. и др. Антитела к различным фосфолипидам у больных с системной красной волчанкой и первичным антифосфолипидным син- дромом. Клиническая медицина. 1999;77(5):32–7.
61. Решетняк Т.М., Забек Я., Алекберова З.С. и др. Разновидности антифосфолипидных антител у больных системной крас- ной волчанкой и первичным антифосфолипидным синдро- мом. Научно-практическая ревматология. 2005;43(5):11–8. DOI: 14412/1995–4484–2005–34.